This systematic review was conducted following the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [30] and has not been registered in PROSPERO. 2.1. Eligibility Criteria The criteria for inclusion were: (1) the study population consisted of pat...
The following two optimal genes, SPRY4 (rank 8) and BCL11A (rank 9), act differentially on the three glioma subtypes according to recent publications. No direct evidence confirmed that SPRY4 may act differentially in glioblastoma and the two astrocytomas. However, a recent study confirmed that...
Despite an overall modest benefit, clinical trials demonstrated the potential of pazopanib to change the natural history of SS with patient outcomes characterized by high heterogeneity, including non-responders and long-term responders [11,18,19]. Similar to other clinically available targeted therapies...
In this study, the following hybrid method is proposed, combining the advantages of both approaches. A filter feature selection algorithm called RELIEF [23] was applied, which proved to be very simple and efficient for evaluating feature qualities. The key idea of the RELIEF algorithm is to ...